PRECIGEN, INC. Proceeds from Issuance of Convertible Preferred Stock
PRECIGEN, INC. (PGEN) reported Proceeds from Issuance of Convertible Preferred Stock of $0 for the 12-month period ending 2015-12-31, per its 10-K filed 2016-02-29.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfConvertiblePreferredStock · last filed 2016-02-29
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2014-12-31 was $0.00.
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2013-12-31 was $0.00.
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for the quarter ending 2013-09-30 was $0.00.
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for fiscal 2015 was $0.00.
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- PRECIGEN, INC. proceeds from issuance of convertible preferred stock for fiscal 2013 was $150.00M.
| Period end | Proceeds from Issuance of Convertible Preferred Stock 3 month | Proceeds from Issuance of Convertible Preferred Stock 6 month | Proceeds from Issuance of Convertible Preferred Stock 9 month | Proceeds from Issuance of Convertible Preferred Stock 12 month |
|---|---|---|---|---|
| 2015-12-31 | $0.00 10-K · filed 2016-02-29 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 10-K · filed 2016-02-29 | ||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $0.00 derived: sum of 2 quarters · filed 2016-02-29 | $150.00M 10-K · filed 2016-02-29 | |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $150.00M 10-Q · filed 2014-11-13 | ||
| 2013-06-30 | $150.00M 10-Q · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |